Article 38 requires the sponsor to notify the Member States concerned within 15 days of a temporary halt or early termination of the clinical trial for reasons of subject safety. The notification must include the reasons, follow-up measures for enrolled subjects, and the safety-information dissemination plan.
The graph holds this control, the 0 it maps to, and the evidence behind each claim, over MCP and REST.